Dr Lal Path Management Guidance Tracker

Management reiterated confidence in delivering 11-12% organic revenue growth for the full fiscal year.

Management stated no price increase is expected for at least 2-3 quarters after passing on GST benefits.

Management expects revenue growth of 13-15% in FY27, driven by network maturation, sustained Delhi NCR growth, and Suburban recovery.

Management guided for EBITDA margin between 27-28% for FY26, despite GST pass-through and labor code impact.

EBITDA margin expected to remain in 27-28% range as investments in labs, R&D, and infrastructure continue.

Capex for FY26 expected at ₹150-160 crore, including investments in radiology centers and precision diagnostic center.

Capital expenditure planned for 12-15 new labs, precision lab setup, and one or two radiology centers.